This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tayek, J. A. Articles by Chlebowski, R. T. Search for Related Content PubMed PubMed Citation Articles by Tayek, J. A. Articles by Chlebowski, R. T. Social Bookmarking                         What's this?

Metabolic Response to Chemotherapy in Colon Cancer Patients

UCLA School of Medicine Department of Medicine and the Clinical Research Center, Harbor-UCLA Medical Center, Torrance, California

Rowan T. Chlebowski, MD, PHD

UCLA School of Medicine Department of Medicine and the Clinical Research Center, Harbor-UCLA Medical Center, Torrance, California

The goal of this investigation was to identify the metabolic abnormalities in a group of colon cancer patients before and during 5-fluorouracil chemotherapy. Twenty-two colon cancer patients were prospectively enrolled into a Clinical Research Center for measurement of counter regulatory hormones, fasting hepatic glucose production (HGP), intravenous glucose tolerance test, plasma leucine appearance (LA), and leucine oxidation (LO). Both the cancer group and the normal volunteers were matched for nutrition status (109 ± 5% of ideal body weight us 104 ± 4%, mean ± SEM, respectively) and history of weight loss (6.3 ± 2.6 kg vs 4.4 ± 4.8). Plasma growth hormone was significantly elevated in the colon cancer patients (3.22 ± 0.62 ng/mL us 0.73 ± 0.18, p < .05) despite the fact that insulin-like growth factor-1 levels were not different. Plasma glucose, insulin, cortisol, glucagon, epinephrine, and norepinephrine levels were not significantly different than those of the normal volunteers. Fasting HGP rates were slightly but not significantly elevated in the group of colon cancer patients compared with the normal volunteers (2.09 ± 0.11 mg/kg per minute us 1.79 ± 0.10, p = .10). Plasma LA was not significantly elevated in the colon cancer group (63.3 ± 3.0 µmol/kg per hour vs 57.7 ± 4.2; p = .25). Five days of continuous 5-fluorouracil chemotherapy was associated with a significant elevation in both the fasting glucose level (97 ± 3 mg/dL vs 106 ± 5, p < .05), and HGP (2.09 ± 0.11 mg/kg per minute us 2.27 ± 0.10; p < .05). The increased fasting glucose value was associated with an increase in the insulin response to the intravenous glucose tolerance test. LA was not affected by the chemotherapy infusion (63.3 ± 3.0 µmol/kg per hour us 58.4 ± 3.0). In contrast, LO was significantly increased (11.5 ± 1.1 µmol/kg per hour us 13.0 ± 1.0, p < .05) and leucine incorporation into protein was significantly decreased (51.2 ± 2.7 µmol/kg per hour us 45.4 ± 2.7, p < .05) while the patients received chemotherapy. Evaluating all the the counter-regulatory hormone measurements demonstrated a significant correlation between the mean HGP and growth hormone levels (r = .446; p < .05). Twenty-four-hour growth hormone pulse frequency in a patient with diffuse carcinoma was 2.5 times the normal rate compared with a sex-and weight-matched normal volunteer. The HGP rate was increased from 1.7 mg/kg per minute to 2.12 mg/kg per minute in the cancer patient. Further work is in progress to identify the possible association between growth hormone physiology and the elevation in fasting HGP observed in cancer patients. (Journal of Parenteral and Enteral Nutrition 16:675-71S)

Journal of Parenteral and Enteral Nutrition, Vol. 16, No. 6 Suppl, 65S-71S (1992)
DOI: 10.1177/014860719201600606


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?